Cell Line Development New

Built Around Your Biologics Journey

Whether you are developing a novel therapeutic or advancing a biosimilar, our solutions are designed with your goals in mind. From host cell line selection to IND-ready packages, we support every stage of your development.

When you choose Aragen, you are partnering with a leader that works as an extension of yours—focused on solving your biggest technical challenges while unlocking the full potential of your product.

What Sets Our CLD Services Apart?

We do not believe in one-size-fits-all. Our approach is flexible, efficient, and fully customized to your biopharmaceuticals, your timelines, and your success.

• Broad Host Cell Line and Vector Capabilities : We are proficient in working with multiple host cell lines including CHO DG44, CHO GS, SP2/0, and NS0, and we support various expression systems such as DHFR, GS, and antibiotic resistance vectors—giving you the flexibility to choose the best-fit system for your therapeutic.
• Deep Expertise Across Biologics : We have successfully expressed a wide range of proteins including human, mouse, canine, and feline IgGs, fusion proteins, enzymes, cytokines, hormones, mini-bodies, and bispecific antibodies—even complex or hard-to-express candidates.
• RapTr2022: Fast-Track Platform for Complex Projects : Our RapTr2022 platform is built for speed and performance. Leveraging our proven CHO-DG44 and CHO-GS systems, it is ideal for clients needing to express difficult proteins or meet accelerated timelines.
• Three Decades of Scientific Depth : We bring more than 30 years of expertise in engineered cell lines and biologics development—ensuring your product is built on a foundation of science and strategy.

Your Fast Track to IND: Seamless, Stable Cell Line Development

Bringing your biologic to market starts with a stable, high-yielding cell line. Our streamlined process is designed to move you efficiently from DNA to Research Cell Bank (RCB)—helping you file your IND with confidence.

With over 200 successful CLD projects and 100+ advancing to clinical phases, we have proven our ability to deliver high-quality results, fast.

Platform Overview: Scalable, Regulatory-Ready Solutions

Aragen Bioscience offers a full spectrum of cell line development services that ensure robust, scalable, and regulatory-compliant production.

CHO-DG44 Platform

Trusted for stability and high productivity—an ideal choice for biosimilar development.

• Royalty-free and low-risk
• >4g/L protein yield in ~18 weeks
• IND-/BLA-ready data packages
• Expertise in biosimilar development

CHO-GS Platform

Robust and versatile, built around a proprietary GS-expression vector.

• Royalty-free, stable expression platform
• Mini pools up to 4.2g/L | Bulk pools up to 700mg/L
• Single cell clones (SCC) up to 6g/L in fed-batch flasks
• 60+ days of stability in growth and productivity
• Optimized from transfection to SCC in just 16 weeks

RapTr2022: The Express Lane to IND

If time is your top priority, RapTr2022 delivers.

• Royalty-free, cost-efficient, and fast
• Up to 6g/L protein expression
• DNA transfection to Research Cell Bank (RCB) in just 18 weeks
• Advanced imaging ensures clonality and consistency
• Built for fast-track biologics and accelerated IND filings

CLD Workflow

Parallel Cell Line Development: Reduce Risk, Maximize Return

Choosing the right expression platform can be a make-or-break decision. We mitigate risk by offering parallel development—testing multiple platforms in tandem so you can identify the best-performing line early. Once a lead is confirmed, alternate tracks are paused, saving time and resources without delaying your IND.

Specialized Biosimilar Support

As the biosimilar market continues to grow, we help you capitalize on it. Our team is equipped to manage the scientific and regulatory complexity of biosimilar development with precision.

• Structural Equivalence: Develop biosimilars that mirror innovator drugs in safety, structure, and efficacy
• Process Optimization: Tailored solutions for scale-up and cost-effective production
• Therapeutic Area Expertise: Inflammatory diseases, oncology, rare genetic disorders, and more

The Aragen Advantages

We’re more than a vendor—we’re a long-term partner invested in your product’s success.

• 200+ successful CLD programs
• 100+ IND-enabling projects
• 5-month CLD timelines for faster market entry
• Diverse platform offerings: CHO DG44, CHO GS, RapTr2022
• Proprietary vectors and analytical rigor
• Bioreactor evaluation and long-term stability studies
• Full CMC support from clone selection to tech transfer
• Expertise in therapeutic, diagnostic, and veterinary biologics
• Parallel development reduces risk and budget pressure